A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot that can protect babies from respiratory syncytial virus, adding an additional tool against the most common cause of hospitalization in infants.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

The Centers for Disease Control and Prevention's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for respiratory syncytial virus (RSV). The Advisory Committee on Immunization Practices (ACIP) voted 5-2 to recommend clesrovimab,